Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / *W EXP 99/99/999
-
Total 13F shares
-
1,306,973
-
Share change
-
-13,542
-
Total reported value
-
$12,322,274
-
Price per share
-
$8.99
-
Number of holders
-
10
-
Value change
-
-$180,493
-
Number of buys
-
1
-
Number of sells
-
3
Institutional Holders of NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) as of Q1 2025
As of 31 Mar 2025,
NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,306,973 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., Affinity Asset Advisors, LLC, Bain Capital Life Sciences Investors, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Laurion Capital Management LP, Vestcor Inc, WOLVERINE ASSET MANAGEMENT LLC, UBS Group AG, and CIBC Private Wealth Group LLC.
This page lists
10
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.